Ceptaris Therapeutics, Inc.
http://www.ceptaris.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Ceptaris Therapeutics, Inc.
Tech Transfer Roundup: Vanderbilt Teams With Deerfield; Expands Cancer Pact With Boehringer
Vanderbilt launches new biotech with Deerfield aimed at reworking the drug development paradigm, while also expanding its cancer research work with BI. Grunenthal partners with Katholieke Universiteit Leuven to investigate ion channel modulation approaches in pain.
Start-Up Quarterly Statistics: Early Funding Declined, But Deal Dollars Flowed
A review of biopharma startup dealmaking and financing activity from January through March 2017, based on data from Strategic Transactions, showed a 19% decline in startup financing compared with the fourth quarter of 2016, but big pharmas provided capital in the form of alliance fees.
Tech Transfer Roundup: Ohio State Turns To Industry Exec To Optimize Assets Before A Deal
Jeffrey Patrick joins Ohio State's effort to develop cancer drugs from internal research, bringing a biopharma viewpoint to optimizing such programs before the deal-making effort starts. Plus, the EMA sets a framework for academic interaction, and more tech transfer news.
PatientsLikeMe Pioneers Social Medicine
The social media site, now in its second decade, has over 350,000 users who report on more than 2,500 diseases. It has begun partnering with biopharma companies eager to engage with members and mine patient-reported data on diseases and outcomes.
Company Information
- Other Names / Subsidiaries
-
- Yaupon Therapeutics, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice